BPG is committed to discovery and dissemination of knowledge
Prospective Study
©The Author(s) 2025.
World J Psychiatry. Nov 19, 2025; 15(11): 109331
Published online Nov 19, 2025. doi: 10.5498/wjp.v15.i11.109331
Table 1 Baseline characteristics of study participants
Characteristic
Low-frequency group (n = 40)
Medium-frequency group (n = 40)
High-frequency group (n = 40)
P value
Demographic and clinical characteristics
Age (years)52.4 ± 8.753.1 ± 9.251.8 ± 8.50.814
Sex (male/female)18/2219/2117/230.925
Body mass index (kg/m²)26.8 ± 3.627.1 ± 3.926.5 ± 3.40.763
Waist circumference (cm)92.4 ± 10.293.1 ± 11.591.8 ± 9.80.842
Duration of prediabetes (months)18.7 ± 10.319.5 ± 11.217.9 ± 9.50.789
Glycemic parameters
Fasting plasma glucose (mmol/L)6.38 ± 0.426.41 ± 0.396.35 ± 0.410.810
2-hour postprandial glucose (mmol/L)9.23 ± 1.159.17 ± 1.099.31 ± 1.180.847
Glycosylated hemoglobin (%)6.14 ± 0.326.17 ± 0.296.11 ± 0.310.688
Insulin parameters
Fasting insulin (μIU/mL)14.76 ± 5.2114.92 ± 5.3814.58 ± 5.120.957
2-hour postprandial insulin (μIU/mL)78.45 ± 25.7379.18 ± 26.4177.69 ± 24.930.968
Homeostasis model assessment of insulin resistance4.17 ± 1.484.23 ± 1.524.09 ± 1.430.910
Oxidative stress markers
Cysteine-C (mg/L)0.92 ± 0.180.93 ± 0.190.91 ± 0.170.873
Beta-2-microglobulin (mg/L)1.98 ± 0.412.01 ± 0.441.95 ± 0.390.804
Malondialdehyde (nmol/mL)5.27 ± 1.235.34 ± 1.295.21 ± 1.180.886
Total antioxidant capacity (U/mL)9.84 ± 2.639.78 ± 2.599.91 ± 2.680.975
Inflammatory markers
High-sensitivity C-reactive protein (mg/L)3.14 ± 1.523.19 ± 1.573.08 ± 1.480.947
Tumor necrosis factor-alpha (pg/mL)12.67 ± 3.9812.78 ± 4.0512.51 ± 3.890.953
Interleukin-6 (pg/mL)3.28 ± 1.213.34 ± 1.253.22 ± 1.170.901
Psychological parameters
Beck Depression Inventory-II score15.82 ± 5.7316.04 ± 5.9115.69 ± 5.620.959
STAI-State score41.35 ± 8.6741.73 ± 8.9440.98 ± 8.420.928
STAI-Trait score43.19 ± 9.2543.58 ± 9.4442.87 ± 9.130.952
Perceived Stress Scale score19.85 ± 5.3720.12 ± 5.4919.67 ± 5.280.924


Write to the Help Desk